The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 8 rounds in the feed, most often in Biotech.
Venture capitalmedicxi.comRounds from 2023-08-23 to 2026-08-11
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Vaderis Therapeutics Breakthrough therapies for patients with Hereditary Hemorrhagic Telangiectasia (HHT) and other rare vascular diseases. | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $152M | 2026-08-11 | [ PART ] |
Series D+ Verified against 1 of 6 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. |
| $67.4M |
| 2026-07-07 |
| [ LEAD ] |
Ethyreal Bio Ethyrealbio develops investigational therapies targeting Thyroid Eye Disease and Graves' Disease for patients. | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $101M | 2026-06-10 | [ LEAD ] |
D3 Bio D3 Bio develops innovative and efficacious medicines focused on oncology and immunology, targeting unmet patient needs. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $108M | 2025-12-09 | [ PART ] |
FORE Biotherapeutics A cancer therapeutics company developing targeted treatments for hard-to-treat tumours | Series D+ Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $38M | 2025-05-22 | [ PART ] |
Curevo Curevo Inc. develops an adjuvanted subunit vaccine for the prevention of shingles in adults. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2025-03-17 | [ LEAD ] |
D3 Bio D3 Bio develops innovative and efficacious medicines focused on oncology and immunology, targeting unmet patient needs. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $62M | 2024-04-08 | [ LEAD ] |
FORE Biotherapeutics A cancer therapeutics company developing targeted treatments for hard-to-treat tumours | Series D Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $75M | 2023-08-23 | [ LEAD ] |